Squamous cell carcinoma

Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound

Retrieved on: 
Friday, February 10, 2023
Translational research, General Hospital, Breast cancer, IND, Pancreatic cancer, McGill University Health Centre, Hospital, Medical research, Department of Oncology, University of Cambridge, Sunlight, Squamous cell carcinoma, Jewish General Hospital, Research, Uterine sarcoma, Pharmaceutical industry, Cancer

The research effort will be focused on advancing the development of Sunshine Biopharma’s Adva-27a anticancer compound through the IND-enabling studies.

Key Points: 
  • The research effort will be focused on advancing the development of Sunshine Biopharma’s Adva-27a anticancer compound through the IND-enabling studies.
  • At any time the research results become conclusive and Sunshine Biopharma wishes to proceed to conducting a Phase I clinical trial, the Jewish General Hospital is prepared to negotiating a new agreement to define the responsibilities and obligations of the parties for such Phase I clinical trial to be performed.
  • The research will be conducted under the direction of Dr. Gerald Batist, Head of the Department of Oncology at the Jewish General Hospital and Director of the McGill Center for Translational Research in Cancer (MCTRC) based at the Lady Davis Institute for Medical Research.
  • “The Jewish General Hospital is one of the leading cancer centers in North America and we are delighted to work with their world renowned oncology physician and research scientist, Dr. Gerald Batist,” said Dr. Steve Slilaty CEO of Sunshine Biopharma.

23andMe Reports FY2023 Third Quarter Financial Results

Retrieved on: 
Wednesday, February 8, 2023
Lijun International Pharmaceutical (Holding) Co. Ltd., Genetics, Machine learning, Annual general meeting, Marketing, PGS, Research, Telehealth, Food, American Society of Human Genetics, Food and Drug Administration, Family, Tax, Society, ASH, Squamous cell carcinoma, Advertising, ATM, Marker beacon, Wilms' tumor, Webcast, Society for Immunotherapy of Cancer, Immunotherapy, Genome, Human genetics, CD200R1, Drug development, EBITDA, Ashkenazi Jews, SAN, National Human Genome Research Institute, Clinical trial, Keith Lemon's LemonAid, FDA, Agricultural Research Service, Consumer service, GSK, Asthma, Interim, Growth, ASHG, Johns Hopkins, SITC, NHGRI, Therapy, Simvastatin, Pharmaceutical industry, Central Europe, Adjustment

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the third quarter (Q3) of its fiscal year 2023 (FY2023), which ended December 31, 2022. 23andMe is the only company with multiple U.S. Food and Drug Administration (FDA) authorizations for over-the-counter genetic health risk reports, and in particular the only company the FDA has authorized to provide, without physician involvement, genetic cancer risk reports and medication insights on how individuals may process certain commonly prescribed medications based on their genetics. The Company has also created the world’s largest crowdsourced platform for genetic research, which it is using to pursue drug discovery programs rooted in human genetics across a spectrum of disease areas.

Key Points: 
  • These reports are developed by 23andMe scientists using data and insights gathered from thousands of customers who have consented to participate in our research.
  • “Our fiscal third quarter results reflect solid revenue growth in our consumer business, despite the macro-economic headwinds, and give us confidence to raise our full year financial guidance,” said Joe Selsavage, Interim Chief Financial and Accounting Officer of 23andMe.
  • 23andMe is raising its full year guidance following Q3 FY2023 results.
  • 23andMe will host a conference call at 4:30 p.m. Eastern Time on Wednesday, February 8, 2023 to discuss the financial results for Q3 FY2023 and report on business progress.

Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue Guidance

Retrieved on: 
Tuesday, February 7, 2023
Marketing, Education, COVID-19, Catalyst Pharmaceuticals, Acquisition, LEMS, Total revenue, Epilepsy, Patient, Squamous cell carcinoma, Eisai, Growth, Degenerative disease, Renewable energy, Video game, Pharmaceutical industry, Catalysis

"2022 was an exceptional year for Catalyst, as we delivered record performance driven by consecutive quarterly revenue growth.

Key Points: 
  • "2022 was an exceptional year for Catalyst, as we delivered record performance driven by consecutive quarterly revenue growth.
  • Catalyst expects to report its 2022 fourth quarter and full year results of operations on or about March 15, 2023.
  • Fourth quarter 2022 total revenues are estimated to be approximately $61 million, compared to total revenues of approximately $38 million in the fourth quarter of 2021, representing an increase of approximately 61% year-over-year.
  • Full year 2022 total revenues are estimated to be approximately $214 million, compared to total revenues of $141 million for 2021, representing an increase of approximately 52% year-over-year.

Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer

Retrieved on: 
Wednesday, January 25, 2023
Kite Pharma, AACR, Disease, Research, Squamous cell carcinoma, Clinical Cancer Research, Cancer, DLL3, Survival, Allogenes, CAR, Patient, SAN, Neoplasm, Fragment crystallizable region, SCLC, Overalls, Therapy, American Association for Cancer Research, Medical imaging, Vaccine

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the publication of a preclinical study demonstrating delta-like ligand 3 (DLL3) is a promising tumor target for AlloCAR T™ in small cell lung cancer (SCLC).

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the publication of a preclinical study demonstrating delta-like ligand 3 (DLL3) is a promising tumor target for AlloCAR T™ in small cell lung cancer (SCLC).
  • The findings were published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).
  • This study describes the selection of ALLO-213 as an allogeneic CAR T development candidate targeting DLL3 from a large number of single chain variable fragment (scFv)-based anti-DLL3 CAR candidates.
  • The selection of ALLO-213 was based on potency and specificity against SCLC cell lines in vitro and in vivo, including cell lines with very low antigen density to establish sensitivity.

Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the ASCO GU Cancer Symposium

Retrieved on: 
Wednesday, January 25, 2023
TLT, Virus, Society, NMIBC, Studie II, American Society of Clinical Oncology, Trial of the century, Cancer, Poster, Prostate cancer, University of Toronto, Metabolic Technologies, Inc., Squamous cell carcinoma, FRCSC, University Health Network, University, ASCO, Interim, Princess Margaret Cancer Centre, Bacteria, Surgical oncology, Research, Pharmaceutical industry, Patient, Urology

The GU-ASCO cancer symposium will take place between February 16th to 18th, 2023 in San Francisco, California with the poster presented for general viewing and discussion within Poster Session B: Prostate Cancer and Urothelial Carcinoma on February 17, 2023 at 12:30 PM to 2:00 PM and 5:15 PM to 6:15 PM.

Key Points: 
  • The GU-ASCO cancer symposium will take place between February 16th to 18th, 2023 in San Francisco, California with the poster presented for general viewing and discussion within Poster Session B: Prostate Cancer and Urothelial Carcinoma on February 17, 2023 at 12:30 PM to 2:00 PM and 5:15 PM to 6:15 PM.
  • The poster titled: “A Phase II Clinical Study of Intravesical Photo Dynamic Therapy in Patients with BCG-Unresponsive NMIBC (interim analysis)” will be presented by the lead author, Girish Kulkarni M.D., Ph.D., FRCSC, Divisions of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Professor, University of Toronto, (Toronto, Ontario, Canada).
  • The poster will include interim clinical data and analysis collected through the enrollment and treatment of patients at all Canadian and US clinical study site by their respective principal investigators for Study II.
  • Arkady Mandel MD, Ph.D., D.Sc., Interim Chief Executive Officer and Chief Scientific Officer, Theralase® stated, “I am delighted that Theralase® will have the opportunity to showcase its latest reported interim clinical data and analysis for Study II at the coveted ASCO GU Cancer Symposium to leading uro-oncologists from around the world.”

ORYZON Announces First Patient In in NET, a Collaborative Phase II Basket Study With Iadademstat in R/R Patients With Neuroendocrine Carcinomas

Retrieved on: 
Wednesday, January 18, 2023
NEC Laboratories America, Prognosis, LSD1, Cancer, AML, Acute myeloid leukemia, Phases of clinical research, Assistant Chief of the Air Staff, Safety, Azacitidine, MD, FDA, Squamous cell carcinoma, ALICE, Hematological Cancer Research Investment and Education Act, Genomics, B cell, ASH, NETS, Patient, Survival, Prevalence, ORY, Fox Chase Cancer Center, FCCC, Research, ORR, ISIN, Paclitaxel, Gastrointestinal tract, NEC, Pharmaceutical industry, SCLC, EU

The trial will assess the safety and efficacy of iadademstat in combination with paclitaxel in patients with relapsed/refractory small cell lung cancer or extrapulmonary high grade NECs.

Key Points: 
  • The trial will assess the safety and efficacy of iadademstat in combination with paclitaxel in patients with relapsed/refractory small cell lung cancer or extrapulmonary high grade NECs.
  • Neuroendocrine neoplasms are rare and heterogeneous cancers arising from neuroendocrine cells, representing 0.5% of all newly diagnosed malignancies, with a prevalence of 100,000 cases in the US.
  • Patients often rapidly develop progressive disease after first line cytotoxic chemotherapy and lack clearly efficacious second line treatment options.
  • Iadademstat has orphan drug designation for SCLC in the US and for AML in the US and EU.

Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium

Retrieved on: 
Tuesday, January 17, 2023
Pancreas, Cancer, ASCO, Neoplasm, FGFR2, Part, Next, Pharmacokinetics, Safety, American Society of Clinical Oncology, Progress, Squamous cell carcinoma, Irreversible, Patient, ICC, Cholangiocarcinoma, FGFR3, KNTE, SAN, Society, UC, Pharmaceutical industry, FGFR

SAN FRANCISCO and SAN DIEGO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc .

Key Points: 
  • SAN FRANCISCO and SAN DIEGO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc .
  • In preclinical studies, KIN-3248 demonstrated inhibitory activity across a wide range of clinically relevant mutations that drive primary disease and acquired resistance to other FGFR inhibitors.
  • Dose escalation (Part A) will determine the recommended dose and schedule of KIN-3248 for further evaluation in patients with FGFR2 and/or FGFR3 gene alteration-driven cancers.
  • This trial is currently enrolling across multiple sites in the U.S. and Taiwan, with initial dose escalation data anticipated in the second half of 2023.

Commonwealth Dermatology Is First in Massachusetts to Offer Non-Surgical Treatment for Common Skin Cancers

Retrieved on: 
Tuesday, January 17, 2023
Oncology, State, Therapy, Skin cancer, Pain, Heart, SRT, Commonwealth, Bed, Tanning, Skin, Squamous cell carcinoma, Patient, Mohs surgery, Medical imaging, Dentistry

That state's first installation is at Commonwealth Dermatology in Worcester, where the announcement was made today.

Key Points: 
  • That state's first installation is at Commonwealth Dermatology in Worcester, where the announcement was made today.
  • Image-Guided SRT is the only treatment for nonmelanoma skin cancer (basal and squamous cell carcinomas) that uses ultrasound imaging to help clinicians direct low-level X-ray energy to targeted areas of the skin, killing cancer cells.
  • Sabrina Waqar, D.O., founder of Commonwealth Dermatology, noted, "Nonmelanoma skin cancer is all too common in Massachusetts, affecting some 65,000 individuals annually.
  • Image-Guided SRT is the new standard of care and we are proud to be the first in Massachusetts to offer it."

Multiple Sclerosis Patients in US Left Without Essential Patient Support Program Will Now Receive Equivalent Backing From Cycle Pharmaceuticals Following FDA’s Approval of TASCENSO ODT® (fingolimod)

Retrieved on: 
Tuesday, January 17, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Multiple sclerosis, Disease, Seizure, News, Castleman disease, Infection, Associate, Hospital, Non-Hodgkin lymphoma, Blood, GlaxoSmithKline Pharmaceuticals Ltd, ODT, University, Person, Lymphoma, RRMS, Liver injury, MS, Posterior reversible encephalopathy syndrome, Headache, QT interval, Melanoma, Status epilepticus, Safety, Blood pressure, Macular edema, Squamous cell carcinoma, FDA, MD, Risk, Angioedema, Sinusitis, Pediatrics, Hives, Vaccine, Bradycardia, Rash, Tongue, Children's Hospital Los Angeles, AV, Water, Patient, History, Medicine, Neurology, Abdominal pain, Stroke, Back pain, Arrhythmia, MRI, Hypersensitivity, Myocardial infarction, Cough, Incidence, Diarrhea, Pain, Excipient, Food, Generic drug, Pharmaceutical industry, Health insurance, Medical device, Fingolimod, Cycle

To find out more about TASCENSO ODT and Cycle Vita please visit www.tascenso.com and www.cyclevita.life respectively.

Key Points: 
  • To find out more about TASCENSO ODT and Cycle Vita please visit www.tascenso.com and www.cyclevita.life respectively.
  • Due to a risk for bradyarrhythmia and AV blocks patients should be monitored during TASCENSO ODT treatment initiation.
  • Use of live attenuated vaccines during, and for 2 months after stopping TASCENSO ODT, should be avoided.
  • To report SUSPECTED ADVERSE REACTIONS, contact Cycle Pharmaceuticals Ltd at 1-888-533-1625 or the FDA at: 1-800-FDA-1088 or www.fda.gov/medwatch .

2022 Hidradenitis Suppurativa (HS) Epidemiology Forecast to 2032: The US has the Largest Number of Affected People - ResearchAndMarkets.com

Retrieved on: 
Monday, January 16, 2023
Biotechnology, Pharmaceutical, Health, Hidradenitis suppurativa, National Organization for Rare Disorders, Crohn's disease, Groin, Dermis, Epidemiology, Sarcoidosis, Skin, National Organ Transplant Act of 1984, Scar, CD, Squamous cell carcinoma, Diagnosis, Patient, Abscess, Organizing, Biopsy, Health Data Insight, Hidradenitis, Fibrosis, Vaccine, Renewable energy, Dietary supplement, Animal, Medicine, Pharmaceutical industry, HS

The epidemiology segment also provides the Hidradenitis Suppurativa epidemiology data and findings across the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Key Points: 
  • The epidemiology segment also provides the Hidradenitis Suppurativa epidemiology data and findings across the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • Among the EU-5 countries, Germany accounted for the highest number of Hidradenitis Suppurativa cases, whereas Spain accounted for the lowest cases in 2021.
  • A detailed review of Hidradenitis Suppurativa epidemiology forecast is included in the report, covering the 7MM drug outreach.
  • The Hidradenitis Suppurativa Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies.